Novo Nordisk Diabetes Products

News

CEO of Novo Nordisk, Maker of Weight Loss Drug Wegovy

Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker

CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an all-time high in the markets. Despite being the first-to-market in the latest generation of GLP-1 drugs,

Benzinga · 3d

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

Contract Pharma · 2d

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.

Healthline2d

FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Seeking Alpha2d

Ignore The Noise - Novo Nordisk Is A Clear Buy

And when talking about growth we usually focus on diabetes, GLP-1 and obesity because these products drove revenue growth in the last few years for Novo Nordisk. However, we should not ignore ...

1don MSN

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

PMLive1d

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

pharmaphorum1d

Novo Nordisk's dropping share price spells the end for CEO

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Novo Nordisk ousts boss as Ozempic maker battles slump

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results